No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...

Treatment with tolebrutinib led to greater confirmed disability improvement at 6 months compared with placebo in patients ...

The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.

FDA-approved treatments for spinal muscular atrophy differ in their mechanisms of action, safety profiles, and administration ...

An Oldham man whose multiple sclerosis (MS) left him unable to pick himself up off the floor is jumping out of a plane this ...

Moolah has had NIL deals of varying degrees with more than 80 basketball players. They include UConn's Caroline Ducharme and ...

Six young people from the Sleaford area have been honoured for their courage and fortitude in coping with the tough hand that ...

Barry Singer, MD, explains why setting realistic expectations about MS treatments is key to managing the disease effectively.